MD Anderson Gynecologic SPORE for Uterine Cancers View Homepage


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

2003-2021

FUNDING AMOUNT

27564267 USD

ABSTRACT

Overall SUMMARY/ABSTRACT The overall goal of the Endometrial (Uterine) Cancer SPORE at MD Anderson Cancer Center is to conduct highly innovative translational research for the prevention and treatment of endometrial cancer. Encompassed within this broad overall goal are the following more specific goals: 1) develop novel therapeutic strategies for advanced/recurrent endometrial cancer and aggressive subtypes; 2) promote novel strategies for unmet clinical needs in prevention and conservative therapy of high-risk precancerous lesions and low grade endometrial cancer; 3) incorporate molecular diagnostics into clinical decision-making; and 4) recruit and support new investigators in endometrial cancer research through the Career Enhancement and Developmental Research Programs. Over the last 5 years, our SPORE has led the field with a highly productive translational research team that has helped to define the clinical and molecular heterogeneity of endometrial cancer. This proposal includes 4 translational research projects addressing scientific problems that span the breadth of endometrial cancer heterogeneity in an effort to impact as many patients as possible. Project 1, ?Novel Targeted Strategies for Prevention and Conservative Management of Complex Atypical Hyperplasia and Grade 1 Endometrioid Endometrial Cancer,? includes a phase II trial using the mTOR inhibitor everolimus to improve standard conservative therapy (progestin-eluting intrauterine device) and is paired with innovative molecular profiling and pharmacologic approaches to further advance conservative treatment options. Project 2, ?CTNNB1 Mutation and Wnt Pathway Activation Define Clinically Aggressive Endometrioid Endometrial Carcinoma,? focuses on targeted therapeutics and molecular mechanisms underlying a clinically aggressive subtype of endometrioid endometrial cancer that is driven through beta-catenin mutation and downstream Wnt pathway activation. Project 3, ?EphA2 Targeting in Uterine Carcinoma,? focuses on the therapeutic target, EphA2. EphA2 is overexpressed especially in higher grade endometrioid carcinomas and in serous carcinoma and is associated with poor overall survival. A phase I clinical trial will evaluate the efficacy and toxicity of a novel therapeutic (EPHARNA) that targets EphA2 by delivering short interfering RNA into tumor cells via a neutral liposome nanovehicle. This therapeutic was developed by Project 3 investigators. Project 4, ?A Framework for Identification of Novel Targeted Therapy Combinations in Endometrial Cancer,? will evaluate tumor molecular changes from samples procured during a combinatorial trial of PARP and PI3K pathway targeted therapy to identify biomarkers of benefit for patients with endometrial cancer. This is paired with implementing a platform to evaluate mechanisms responsible for adaptive resistance to targeted therapies in order to enable a rational design of improved combination therapies. Four Cores will support these projects- Administrative Core, Pathology Core, Biomarkers Core, and Biostatistics and Bioinformatics Core. More... »

URL

http://projectreporter.nih.gov/project_info_description.cfm?aid=9552040

Related SciGraph Publications

  • 2018-12. Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro in BMC CANCER
  • 2018-12. Personalized Integrated Network Modeling of the Cancer Proteome Atlas in SCIENTIFIC REPORTS
  • 2018-12. Sample size determination for mediation analysis of longitudinal data in BMC MEDICAL RESEARCH METHODOLOGY
  • 2018-12. FABP4 as a key determinant of metastatic potential of ovarian cancer in NATURE COMMUNICATIONS
  • 2018-10. Nuclear β-catenin localization and mutation of the CTNNB1 gene: a context-dependent association in MODERN PATHOLOGY
  • 2017-12. Immune cell profiling in cancer: molecular approaches to cell-specific identification in NPJ PRECISION ONCOLOGY
  • 2017-07. CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence in MODERN PATHOLOGY
  • 2016-11. Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort in MODERN PATHOLOGY
  • 2016-01. An antibody to amphiregulin, an abundant growth factor in patients’ fluids, inhibits ovarian tumors in ONCOGENE
  • 2014-12. A community effort to assess and improve drug sensitivity prediction algorithms in NATURE BIOTECHNOLOGY
  • 2014-12. Gene co-expression network analysis reveals common system-level properties of prognostic genes across cancer types in NATURE COMMUNICATIONS
  • 2014-12. Genome-wide transcriptome profiling of homologous recombination DNA repair in NATURE COMMUNICATIONS
  • 2014-12. The Pan-Cancer analysis of pseudogene expression reveals biologically and clinically relevant tumour subtypes in NATURE COMMUNICATIONS
  • 2014-12. A community computational challenge to predict the activity of pairs of compounds in NATURE BIOTECHNOLOGY
  • 2014-12. Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression in NATURE COMMUNICATIONS
  • 2014-10. PATHOME: an algorithm for accurately detecting differentially expressed subpathways in ONCOGENE
  • 2014-07. Assessing the clinical utility of cancer genomic and proteomic data across tumor types in NATURE BIOTECHNOLOGY
  • 2014-05. Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer in ONCOGENE
  • 2014-03. α-catenin acts as a tumour suppressor in E-cadherin-negative basal-like breast cancer by inhibiting NF-κB signalling in NATURE CELL BIOLOGY
  • 2014-01. Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer in BREAST CANCER RESEARCH AND TREATMENT
  • 2013-12. LKB1 is a central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated breast cancer in CANCER & METABOLISM
  • 2013-12. Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells in CANCER & METABOLISM
  • 2013-12. Tumour angiogenesis regulation by the miR-200 family in NATURE COMMUNICATIONS
  • 2013-11. Favorable modulation of benign breast tissue and serum risk biomarkers is associated with >10 % weight loss in postmenopausal women in BREAST CANCER RESEARCH AND TREATMENT
  • 2013-10. Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas in MODERN PATHOLOGY
  • 2013-06. Transient anabolic effects accompany epidermal growth factor receptor signal activation in articular cartilage in vivo in ARTHRITIS RESEARCH & THERAPY
  • 2012-12. An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays in PROTEOME SCIENCE
  • 2012-10. Deubiquitination of EGFR by Cezanne-1 contributes to cancer progression in ONCOGENE
  • 2012-10. Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer in BREAST CANCER RESEARCH
  • 2012-07. A new isoform of steroid receptor coactivator-1 is crucial for pathogenic progression of endometriosis in NATURE MEDICINE
  • 2012-05. Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing in MODERN PATHOLOGY
  • 2012. Chitosan Nanoparticles in ENCYCLOPEDIA OF NANOTECHNOLOGY
  • 2011-11. Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling in ONCOGENE
  • 2011-09. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway–dependent and PI3K pathway–independent mechanisms in NATURE MEDICINE
  • 2011-07. Management Strategies for Recurrent Platinum-Resistant Ovarian Cancer in DRUGS
  • 2010-12. Arsenic trioxide induces a beclin-1-independent autophagic pathway via modulation of SnoN/SkiL expression in ovarian carcinoma cells in CELL DEATH & DIFFERENTIATION
  • 2010-12. A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers in CLINICAL PROTEOMICS
  • 2010-10-23. Inhibition of the Src Oncogene: Therapeutic Potential in Ovarian Carcinoma in EMERGING THERAPEUTIC TARGETS IN OVARIAN CANCER
  • 2010-07. The synergistic effect of Mig-6 and Pten ablation on endometrial cancer development and progression in ONCOGENE
  • 2010-04. The novel estrogen-induced gene EIG121 regulates autophagy and promotes cell survival under stress in CELL DEATH & DISEASE
  • 2009-12. High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays in BMC MEDICAL GENOMICS
  • 2009-08. S100A4 mediates endometrial cancer invasion and is a target of TGF-β1 signaling in LABORATORY INVESTIGATION
  • 2009-05. DNA methylation inhibits p53-mediated survivin repression in ONCOGENE
  • 2009-03. Oxygen sensor boosts growth factor signaling in NATURE MEDICINE
  • 2009. Ras-Superfamily GTP-ases in Ovarian Cancer in OVARIAN CANCER
  • 2008-11. Derailed endocytosis: an emerging feature of cancer in NATURE REVIEWS CANCER
  • 2008-11. MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers in ONCOGENE
  • 2008-06. Developmental reprogramming of IGF signaling and susceptibility to endometrial hyperplasia in the rat in LABORATORY INVESTIGATION
  • 2007-10. Hypomethylation-induced expression of S100A4 in endometrial carcinoma in MODERN PATHOLOGY
  • 2006-12. Steroid receptor coactivator AIB1 in endometrial carcinoma, hyperplasia and normal endometrium: correlation with clinicopathologic parameters and biomarkers in MODERN PATHOLOGY
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2211", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }
        ], 
        "amount": {
          "currency": "USD", 
          "type": "MonetaryAmount", 
          "value": "27564267"
        }, 
        "description": "Overall SUMMARY/ABSTRACT The overall goal of the Endometrial (Uterine) Cancer SPORE at MD Anderson Cancer Center is to conduct highly innovative translational research for the prevention and treatment of endometrial cancer. Encompassed within this broad overall goal are the following more specific goals: 1) develop novel therapeutic strategies for advanced/recurrent endometrial cancer and aggressive subtypes; 2) promote novel strategies for unmet clinical needs in prevention and conservative therapy of high-risk precancerous lesions and low grade endometrial cancer; 3) incorporate molecular diagnostics into clinical decision-making; and 4) recruit and support new investigators in endometrial cancer research through the Career Enhancement and Developmental Research Programs. Over the last 5 years, our SPORE has led the field with a highly productive translational research team that has helped to define the clinical and molecular heterogeneity of endometrial cancer. This proposal includes 4 translational research projects addressing scientific problems that span the breadth of endometrial cancer heterogeneity in an effort to impact as many patients as possible. Project 1, ?Novel Targeted Strategies for Prevention and Conservative Management of Complex Atypical Hyperplasia and Grade 1 Endometrioid Endometrial Cancer,? includes a phase II trial using the mTOR inhibitor everolimus to improve standard conservative therapy (progestin-eluting intrauterine device) and is paired with innovative molecular profiling and pharmacologic approaches to further advance conservative treatment options. Project 2, ?CTNNB1 Mutation and Wnt Pathway Activation Define Clinically Aggressive Endometrioid Endometrial Carcinoma,? focuses on targeted therapeutics and molecular mechanisms underlying a clinically aggressive subtype of endometrioid endometrial cancer that is driven through beta-catenin mutation and downstream Wnt pathway activation. Project 3, ?EphA2 Targeting in Uterine Carcinoma,? focuses on the therapeutic target, EphA2. EphA2 is overexpressed especially in higher grade endometrioid carcinomas and in serous carcinoma and is associated with poor overall survival. A phase I clinical trial will evaluate the efficacy and toxicity of a novel therapeutic (EPHARNA) that targets EphA2 by delivering short interfering RNA into tumor cells via a neutral liposome nanovehicle. This therapeutic was developed by Project 3 investigators. Project 4, ?A Framework for Identification of Novel Targeted Therapy Combinations in Endometrial Cancer,? will evaluate tumor molecular changes from samples procured during a combinatorial trial of PARP and PI3K pathway targeted therapy to identify biomarkers of benefit for patients with endometrial cancer. This is paired with implementing a platform to evaluate mechanisms responsible for adaptive resistance to targeted therapies in order to enable a rational design of improved combination therapies. Four Cores will support these projects- Administrative Core, Pathology Core, Biomarkers Core, and Biostatistics and Bioinformatics Core.", 
        "endDate": "2021-08-31T00:00:00Z", 
        "funder": {
          "id": "https://www.grid.ac/institutes/grid.48336.3a", 
          "type": "Organization"
        }, 
        "id": "sg:grant.2440196", 
        "identifier": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "2440196"
            ]
          }, 
          {
            "name": "nih_id", 
            "type": "PropertyValue", 
            "value": [
              "P50CA098258"
            ]
          }
        ], 
        "inLanguage": [
          "en"
        ], 
        "keywords": [
          "prevention", 
          "specific goals", 
          "framework", 
          "serous carcinoma", 
          "progestin", 
          "identification", 
          "phase II trial", 
          "breadth", 
          "neutral liposome nanovehicle", 
          "Cores", 
          "translational research projects", 
          "molecular diagnostics", 
          "PI3K pathway", 
          "years", 
          "many patients", 
          "molecular changes", 
          "high grade", 
          "pathology core", 
          "SUMMARY/ABSTRACT", 
          "endometrioid endometrial cancer", 
          "Biostatistics", 
          "mTOR inhibitor everolimus", 
          "therapy", 
          "conservative management", 
          "patients", 
          "new investigators", 
          "overall goal", 
          "therapeutic target", 
          "low grade endometrial cancer", 
          "EphA2 Targeting", 
          "rational design", 
          "efforts", 
          "tumor cells", 
          "novel therapeutics", 
          "conservative treatment options", 
          "adaptive resistance", 
          "endometrial cancer research", 
          "EPHARNA", 
          "intrauterine device", 
          "novel", 
          "therapeutics", 
          "Developmental Research Programs", 
          "molecular heterogeneity", 
          "biomarkers", 
          "career enhancement", 
          "aggressive subtype", 
          "Cancer SPORE", 
          "Project 2", 
          "order", 
          "Uterine Cancers", 
          "PARP", 
          "Wnt Pathway Activation Define Clinically Aggressive Endometrioid Endometrial Carcinoma", 
          "downstream Wnt pathway activation", 
          "uterine carcinoma", 
          "endometrial cancer", 
          "Biomarkers Core", 
          "unmet clinical need", 
          "samples", 
          "toxicity", 
          "therapeutic strategies", 
          "pharmacologic approaches", 
          "Bioinformatics Core", 
          "phase I clinical trial", 
          "productive translational research team", 
          "complex atypical hyperplasia", 
          "standard conservative therapy", 
          "tumor", 
          "Novel Targeted Strategies", 
          "Project 4", 
          "RNA", 
          "Project 3 investigators", 
          "conservative therapy", 
          "beta-catenin mutations", 
          "Novel Targeted Therapy Combinations", 
          "endometrial", 
          "innovative translational research", 
          "combinatorial trials", 
          "novel strategy", 
          "treatment", 
          "innovative molecular profiling", 
          "molecular mechanisms", 
          "recurrent endometrial cancer", 
          "Project 3", 
          "endometrial cancer heterogeneity", 
          "proposal", 
          "combination therapy", 
          "further advances", 
          "Grade 1 Endometrioid Endometrial Cancer", 
          "high-risk precancerous lesions", 
          "platform", 
          "targets EphA2", 
          "MD Anderson Gynecologic SPORE", 
          "Project 1", 
          "mechanism", 
          "projects- Administrative Core", 
          "EphA2", 
          "endometrioid carcinomas", 
          "uterine", 
          "efficacy", 
          "clinical decision-making", 
          "scientific problems", 
          "field", 
          "poor overall survival", 
          "benefits", 
          "MD Anderson Cancer Center", 
          "CTNNB1 mutations", 
          "broad overall goal", 
          "spores"
        ], 
        "name": "MD Anderson Gynecologic SPORE for Uterine Cancers", 
        "recipient": [
          {
            "id": "https://www.grid.ac/institutes/grid.240145.6", 
            "type": "Organization"
          }, 
          {
            "affiliation": {
              "id": "https://www.grid.ac/institutes/grid.240145.6", 
              "name": "UNIVERSITY OF TX MD ANDERSON CAN CTR", 
              "type": "Organization"
            }, 
            "familyName": "LU", 
            "givenName": "KAREN HSIEH", 
            "id": "sg:person.016476556517.19", 
            "type": "Person"
          }, 
          {
            "member": "sg:person.016476556517.19", 
            "roleName": "PI", 
            "type": "Role"
          }
        ], 
        "sameAs": [
          "https://app.dimensions.ai/details/grant/grant.2440196"
        ], 
        "sdDataset": "grants", 
        "sdDatePublished": "2019-03-07T12:11", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/nih_projects_4.xml.gz", 
        "startDate": "2003-09-01T00:00:00Z", 
        "type": "MonetaryGrant", 
        "url": "http://projectreporter.nih.gov/project_info_description.cfm?aid=9552040"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.2440196'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.2440196'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.2440196'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.2440196'


     

    This table displays all metadata directly associated to this object as RDF triples.

    152 TRIPLES      19 PREDICATES      130 URIs      122 LITERALS      5 BLANK NODES

    Subject Predicate Object
    1 sg:grant.2440196 schema:about anzsrc-for:2211
    2 schema:amount Ne186b3716232407e808f5dde1a339bff
    3 schema:description Overall SUMMARY/ABSTRACT The overall goal of the Endometrial (Uterine) Cancer SPORE at MD Anderson Cancer Center is to conduct highly innovative translational research for the prevention and treatment of endometrial cancer. Encompassed within this broad overall goal are the following more specific goals: 1) develop novel therapeutic strategies for advanced/recurrent endometrial cancer and aggressive subtypes; 2) promote novel strategies for unmet clinical needs in prevention and conservative therapy of high-risk precancerous lesions and low grade endometrial cancer; 3) incorporate molecular diagnostics into clinical decision-making; and 4) recruit and support new investigators in endometrial cancer research through the Career Enhancement and Developmental Research Programs. Over the last 5 years, our SPORE has led the field with a highly productive translational research team that has helped to define the clinical and molecular heterogeneity of endometrial cancer. This proposal includes 4 translational research projects addressing scientific problems that span the breadth of endometrial cancer heterogeneity in an effort to impact as many patients as possible. Project 1, ?Novel Targeted Strategies for Prevention and Conservative Management of Complex Atypical Hyperplasia and Grade 1 Endometrioid Endometrial Cancer,? includes a phase II trial using the mTOR inhibitor everolimus to improve standard conservative therapy (progestin-eluting intrauterine device) and is paired with innovative molecular profiling and pharmacologic approaches to further advance conservative treatment options. Project 2, ?CTNNB1 Mutation and Wnt Pathway Activation Define Clinically Aggressive Endometrioid Endometrial Carcinoma,? focuses on targeted therapeutics and molecular mechanisms underlying a clinically aggressive subtype of endometrioid endometrial cancer that is driven through beta-catenin mutation and downstream Wnt pathway activation. Project 3, ?EphA2 Targeting in Uterine Carcinoma,? focuses on the therapeutic target, EphA2. EphA2 is overexpressed especially in higher grade endometrioid carcinomas and in serous carcinoma and is associated with poor overall survival. A phase I clinical trial will evaluate the efficacy and toxicity of a novel therapeutic (EPHARNA) that targets EphA2 by delivering short interfering RNA into tumor cells via a neutral liposome nanovehicle. This therapeutic was developed by Project 3 investigators. Project 4, ?A Framework for Identification of Novel Targeted Therapy Combinations in Endometrial Cancer,? will evaluate tumor molecular changes from samples procured during a combinatorial trial of PARP and PI3K pathway targeted therapy to identify biomarkers of benefit for patients with endometrial cancer. This is paired with implementing a platform to evaluate mechanisms responsible for adaptive resistance to targeted therapies in order to enable a rational design of improved combination therapies. Four Cores will support these projects- Administrative Core, Pathology Core, Biomarkers Core, and Biostatistics and Bioinformatics Core.
    4 schema:endDate 2021-08-31T00:00:00Z
    5 schema:funder https://www.grid.ac/institutes/grid.48336.3a
    6 schema:identifier N356638a4c9aa42818a9db6cb3074f257
    7 N43e089e1c4004f258b9c995b61643b7e
    8 schema:inLanguage en
    9 schema:keywords Bioinformatics Core
    10 Biomarkers Core
    11 Biostatistics
    12 CTNNB1 mutations
    13 Cancer SPORE
    14 Cores
    15 Developmental Research Programs
    16 EPHARNA
    17 EphA2
    18 EphA2 Targeting
    19 Grade 1 Endometrioid Endometrial Cancer
    20 MD Anderson Cancer Center
    21 MD Anderson Gynecologic SPORE
    22 Novel Targeted Strategies
    23 Novel Targeted Therapy Combinations
    24 PARP
    25 PI3K pathway
    26 Project 1
    27 Project 2
    28 Project 3
    29 Project 3 investigators
    30 Project 4
    31 RNA
    32 SUMMARY/ABSTRACT
    33 Uterine Cancers
    34 Wnt Pathway Activation Define Clinically Aggressive Endometrioid Endometrial Carcinoma
    35 adaptive resistance
    36 aggressive subtype
    37 benefits
    38 beta-catenin mutations
    39 biomarkers
    40 breadth
    41 broad overall goal
    42 career enhancement
    43 clinical decision-making
    44 combination therapy
    45 combinatorial trials
    46 complex atypical hyperplasia
    47 conservative management
    48 conservative therapy
    49 conservative treatment options
    50 downstream Wnt pathway activation
    51 efficacy
    52 efforts
    53 endometrial
    54 endometrial cancer
    55 endometrial cancer heterogeneity
    56 endometrial cancer research
    57 endometrioid carcinomas
    58 endometrioid endometrial cancer
    59 field
    60 framework
    61 further advances
    62 high grade
    63 high-risk precancerous lesions
    64 identification
    65 innovative molecular profiling
    66 innovative translational research
    67 intrauterine device
    68 low grade endometrial cancer
    69 mTOR inhibitor everolimus
    70 many patients
    71 mechanism
    72 molecular changes
    73 molecular diagnostics
    74 molecular heterogeneity
    75 molecular mechanisms
    76 neutral liposome nanovehicle
    77 new investigators
    78 novel
    79 novel strategy
    80 novel therapeutics
    81 order
    82 overall goal
    83 pathology core
    84 patients
    85 pharmacologic approaches
    86 phase I clinical trial
    87 phase II trial
    88 platform
    89 poor overall survival
    90 prevention
    91 productive translational research team
    92 progestin
    93 projects- Administrative Core
    94 proposal
    95 rational design
    96 recurrent endometrial cancer
    97 samples
    98 scientific problems
    99 serous carcinoma
    100 specific goals
    101 spores
    102 standard conservative therapy
    103 targets EphA2
    104 therapeutic strategies
    105 therapeutic target
    106 therapeutics
    107 therapy
    108 toxicity
    109 translational research projects
    110 treatment
    111 tumor
    112 tumor cells
    113 unmet clinical need
    114 uterine
    115 uterine carcinoma
    116 years
    117 schema:name MD Anderson Gynecologic SPORE for Uterine Cancers
    118 schema:recipient N82e1c9c328614768bdf06f4b33ae3833
    119 sg:person.016476556517.19
    120 https://www.grid.ac/institutes/grid.240145.6
    121 schema:sameAs https://app.dimensions.ai/details/grant/grant.2440196
    122 schema:sdDatePublished 2019-03-07T12:11
    123 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    124 schema:sdPublisher N6e4943bcd3a44aada3fd8d6c1edc470b
    125 schema:startDate 2003-09-01T00:00:00Z
    126 schema:url http://projectreporter.nih.gov/project_info_description.cfm?aid=9552040
    127 sgo:license sg:explorer/license/
    128 sgo:sdDataset grants
    129 rdf:type schema:MonetaryGrant
    130 N356638a4c9aa42818a9db6cb3074f257 schema:name dimensions_id
    131 schema:value 2440196
    132 rdf:type schema:PropertyValue
    133 N43e089e1c4004f258b9c995b61643b7e schema:name nih_id
    134 schema:value P50CA098258
    135 rdf:type schema:PropertyValue
    136 N6e4943bcd3a44aada3fd8d6c1edc470b schema:name Springer Nature - SN SciGraph project
    137 rdf:type schema:Organization
    138 N82e1c9c328614768bdf06f4b33ae3833 schema:member sg:person.016476556517.19
    139 schema:roleName PI
    140 rdf:type schema:Role
    141 Ne186b3716232407e808f5dde1a339bff schema:currency USD
    142 schema:value 27564267
    143 rdf:type schema:MonetaryAmount
    144 anzsrc-for:2211 schema:inDefinedTermSet anzsrc-for:
    145 rdf:type schema:DefinedTerm
    146 sg:person.016476556517.19 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
    147 schema:familyName LU
    148 schema:givenName KAREN HSIEH
    149 rdf:type schema:Person
    150 https://www.grid.ac/institutes/grid.240145.6 schema:name UNIVERSITY OF TX MD ANDERSON CAN CTR
    151 rdf:type schema:Organization
    152 https://www.grid.ac/institutes/grid.48336.3a schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...